Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BML, Inc. (4694.T)
Tokyo, JP
BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.31% | -9.64% | -12.70% | -15.88% | -5.45% | -9.04% | +23.31% | +11.76% | -4.41% | +48.29% | +77.04% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+4.9% Q1'26: +3.4% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+26.7% Q1'26: +24.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+6.9% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+6.9% Q1'26: +3.4% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+10.1% ★ Q1'26: +4.8% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-2.4% ★ Q1'26: -4.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.25× ★ Q1'26: 0.32× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
104.40B
est: 104.80B (-0.4%)
|
109.02B
est: 108.10B (+0.9%)
|
111.24B
est: 112.01B (-0.7%)
|
113.50B
est: 113.85B (-0.3%)
|
117.13B
est: 117.03B (+0.1%)
|
120.73B
est: 121.45B (-0.6%)
|
138.57B
est: 138.07B (+0.4%)
|
186.07B
est: 177.50B (+4.8%)
|
159.46B
est: 156.76B (+1.7%)
|
137.96B
est: 138.28B (-0.2%)
|
143.19B
est: 142.00B (+0.8%)
|
151.00B
151.00B – 151.00B
+6.3% YoY
|
157.00B
157.00B – 157.00B
+4.0% YoY
|
162.00B
162.00B – 162.00B
+3.2% YoY
|
167.00B
167.00B – 167.00B
+3.1% YoY
|
| EBITDA |
13.04B
est: 19.42B (-32.9%)
|
14.19B
est: 20.03B (-29.2%)
|
14.49B
est: 20.76B (-30.2%)
|
14.67B
est: 21.10B (-30.5%)
|
15.78B
est: 21.69B (-27.2%)
|
14.90B
est: 22.51B (-33.8%)
|
25.39B
est: 25.59B (-0.8%)
|
54.78B
est: 32.89B (+66.5%)
|
30.29B
est: 29.05B (+4.3%)
|
15.96B
est: 24.96B (-36.1%)
|
17.08B
est: 25.63B (-33.4%)
|
27.26B
27.26B – 27.26B
+6.3% YoY
|
28.34B
28.34B – 28.34B
+4.0% YoY
|
29.24B
29.24B – 29.24B
+3.2% YoY
|
30.15B
30.15B – 30.15B
+3.1% YoY
|
| EBIT |
7.06B
est: 14.94B (-52.7%)
|
8.43B
est: 15.41B (-45.3%)
|
9.33B
est: 15.96B (-41.6%)
|
9.34B
est: 16.23B (-42.4%)
|
10.45B
est: 16.68B (-37.3%)
|
9.76B
est: 17.31B (-43.6%)
|
19.94B
est: 19.68B (+1.3%)
|
48.89B
est: 25.30B (+93.3%)
|
23.94B
est: 22.34B (+7.1%)
|
9.17B
est: 19.04B (-51.9%)
|
9.37B
est: 19.56B (-52.1%)
|
20.80B
20.80B – 20.80B
+6.3% YoY
|
21.62B
21.62B – 21.62B
+4.0% YoY
|
22.31B
22.31B – 22.31B
+3.2% YoY
|
23.00B
23.00B – 23.00B
+3.1% YoY
|
| Net Income |
3.87B
est: 3.64B (+6.3%)
|
5.42B
est: 4.47B (+21.3%)
|
5.95B
est: 5.59B (+6.4%)
|
5.99B
est: 5.58B (+7.3%)
|
6.65B
est: 6.12B (+8.7%)
|
6.38B
est: 6.04B (+5.5%)
|
13.71B
est: 12.19B (+12.5%)
|
33.74B
est: 28.76B (+17.3%)
|
15.58B
est: 14.82B (+5.1%)
|
6.04B
est: 5.95B (+1.4%)
|
6.26B
est: 6.10B (+2.7%)
|
7.65B
7.65B – 7.65B
+25.5% YoY
|
8.67B
8.67B – 8.67B
+13.4% YoY
|
9.07B
9.07B – 9.07B
+4.5% YoY
|
10.96B
10.96B – 10.96B
+20.9% YoY
|
| SGA |
29.69B
est: 25.21B (+17.8%)
|
30.16B
est: 26.01B (+16.0%)
|
30.17B
est: 26.95B (+11.9%)
|
30.80B
est: 27.39B (+12.4%)
|
31.50B
est: 28.16B (+11.9%)
|
32.20B
est: 29.22B (+10.2%)
|
34.55B
est: 33.22B (+4.0%)
|
37.76B
est: 42.71B (-11.6%)
|
37.24B
est: 37.72B (-1.3%)
|
36.19B
est: 33.22B (+8.9%)
|
36.24B
est: 34.11B (+6.2%)
|
36.28B
36.28B – 36.28B
+6.3% YoY
|
37.72B
37.72B – 37.72B
+4.0% YoY
|
38.92B
38.92B – 38.92B
+3.2% YoY
|
40.12B
40.12B – 40.12B
+3.1% YoY
|
| EPS |
91.20
est: 93.39 (-2.3%)
|
127.69
est: 114.60 (+11.4%)
|
140.01
est: 143.29 (-2.3%)
|
140.81
est: 143.07 (-1.6%)
|
156.05
est: 156.80 (-0.5%)
|
151.26
est: 154.85 (-2.3%)
|
337.43
est: 312.53 (+8.0%)
|
833.22
est: 737.07 (+13.0%)
|
395.83
est: 379.82 (+4.2%)
|
154.80
est: 152.51 (+1.5%)
|
160.60
est: 156.30 (+2.8%)
|
196.10
196.10 – 196.10
+25.5% YoY
|
222.30
222.30 – 222.30
+13.4% YoY
|
232.40
232.40 – 232.40
+4.5% YoY
|
280.87
280.87 – 280.87
+20.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hideaki Osawa | Exec Officer, Dir of Sales Div, Director of Pharmaceutical Clinical Trial Sales Dept & Director | — | — |
| Hiroyuki Kigoshi | Managing Executive Officer | — | — |
| Kenji Shibata | Executive Officer & Director | — | male |
| Kensuke Kondo | President & Representative Director | — | male |
| Masami Kondo | Executive Officer | — | — |
| Nobuki Arai | Vice President & Representative Director | — | male |
| Norihisa Takebe | Representative Director, Senior Managing Executive Officer and Head of Planning & Sales Division | — | male |
| Yuji Yamashita | Executive Officer, Head of Systems Division & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4694.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
